Kurtzke J F
Adv Neurol. 1982;36:281-302.
Motor neuron disease (MND) is used in this paper as the generic label, encompassing the clinical variants of amyotrophic lateral sclerosis (ALS), progressive myelopathic muscular atrophy (PMMA), and progressive bulbar palsy (PBP). ALS is limited to instances of anterior horn cell plus pyramidal tract involvement. When only anterior horn cell lesions are inferred, either PMMA or PBP is used, depending on the levels of involvement; when both cord and brain stem are affected. PBP is the designation. Mortality data on MND have been available for a number of countries since 1949. The coding used under international rules has varied considerably over this interval. Before 1969, hereditary muscular atrophies were included. Since 1979, no subdivision by type of MND is possible. International death rates for MND have all been rather close to 1 per 100,000 population per year, though perhaps nearer to 1.4 on the average in recent years. There has been an increasing proportion of MND deaths coded to ALS between 1949 and 1977. There is no notable geographic variation among countries, nor within countries such as the U.S. and Denmark. A slight upward trend in death rates over time in the U.S. is matched by a slight decrease in Denmark. Death rates from all sources indicate a male preponderance for ALS or MND as a whole, at about 1.5 to 1, male to female. There is also a consistent predilection by age, with few deaths under age 50 or so and a clear maximum in age-specific death rates at about age 70. This holds for both sexes. In the U.S., there is also a white-nonwhite difference, with a ratio of about 1.6:1 but with age and sex differences similar to whites. Average annual incidence rates from among white occidental populations range mostly between 0.6 and 1.8 per 100,000 population for MND and about 0.8 and 1.5 per 100,000 for ALS. Again a male predilection is seen. There is a clear maximum in age-specific incidence rates at about age 65 in all surveys except that of Rochester, Minnesota, where the age-specific rate for those 75+ years of age is apparently higher than that for those age 65 to 74. Incidence rates, then, are quite similar one land to another. A reported deficit in Mexico may reflect case-selection bias. An excess among Filipinos on Hawaii seems more a function of population age-distributions than a true racial or ethnic difference. Prevalence rates from outside the Orient range from about 1 to 7 per 100,000 population for MND and about 2 to 7 for ALS. Those surveys more likely to be reasonably complete provide ALS prevalence rates of about 4 to 6, and an overall estimate of ALS prevalence of some 5 per 100,000 population is a reasonable figure. In the Orient, most of the MND prevalence rates fall within the same range as in the occident, except for two areas of the Kii peninsula of southern Honshu, Japan, where the reported prevalence rates are some 100 to 200 per 100,000 population. These cases are similar to the Guamanian ALS, both clinically and pathologically...
在本文中,运动神经元病(MND)用作通用标签,涵盖肌萎缩侧索硬化症(ALS)、进行性脊髓性肌萎缩症(PMMA)和进行性延髓麻痹(PBP)的临床变体。ALS仅限于前角细胞加锥体束受累的情况。当仅推断存在前角细胞病变时,根据受累水平使用PMMA或PBP;当脊髓和脑干均受影响时,则使用PBP。自1949年以来,已有多个国家提供了MND的死亡率数据。在此期间,根据国际规则使用的编码有很大差异。1969年以前,遗传性肌萎缩症也包括在内。自1979年以来,无法按MND类型进行细分。MND的国际死亡率每年都相当接近每10万人口1例,不过近年来平均可能更接近1.4例。在1949年至1977年期间,编码为ALS的MND死亡比例一直在增加。各国之间以及美国和丹麦等国家内部均无明显的地理差异。美国死亡率随时间略有上升的趋势与丹麦略有下降的趋势相匹配。所有来源的死亡率表明,ALS或总体MND在男性中占优势,男女比例约为1.5比1。在年龄方面也存在一致的偏好,50岁左右以下很少有死亡病例,年龄特异性死亡率在70岁左右明显最高。男女皆是如此。在美国,白人和非白人之间也存在差异,比例约为1.6比1,但年龄和性别差异与白人相似。西方白人人群的年平均发病率,MND大多在每10万人口0.6至1.8例之间,ALS约为每10万人口0.8至1.5例。同样可见男性偏好。在所有调查中,除了明尼苏达州罗切斯特市的调查外,年龄特异性发病率在65岁左右明显最高,在罗切斯特市,75岁及以上人群的年龄特异性发病率明显高于65至74岁人群。因此,各国的发病率相当相似。墨西哥报告的发病率较低可能反映了病例选择偏差。夏威夷菲律宾人群中发病率较高似乎更多是人口年龄分布的作用,而非真正的种族或民族差异。东方以外地区MND的患病率为每10万人口约1至7例,ALS为约2至7例。那些更可能合理完整的调查提供的ALS患病率约为4至6例,总体估计ALS患病率约为每10万人口5例是合理的数字。在东方,大多数MND患病率与西方处于同一范围,除了日本本州岛南部纪伊半岛的两个地区,报告的患病率约为每10万人口100至200例。这些病例在临床和病理上与关岛的ALS相似……